Edition:
United Kingdom

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
23 Feb 2018
Change (% chg)

$-0.19 (-8.64%)
Prev Close
$2.20
Open
$2.27
Day's High
$2.27
Day's Low
$2.01
Volume
49,961
Avg. Vol
58,930
52-wk High
$22.16
52-wk Low
$2.01

Latest Key Developments (Source: Significant Developments)

Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT.AKARI THERAPEUTICS PLC - NEW DOSING REGIMEN AT 45 MG PER DAY IS EXPECTED TO BE USED IN PHASE III TRIALS.AKARI - PLANS TO COMMENCE TWO PHASE III PNH CLINICAL TRIALS WITH COVERSIN BEGINNING WITH CAPSTONE IN Q1 OF 2018.AKARI THERAPEUTICS PLC - ON TRACK TO PROGRESS INTO PHASE III CLINICAL TRIALS IN Q1 OF 2018.AKARI THERAPEUTICS PLC - SECOND PHASE III TRIAL, ASSET, IS PLANNED FOR H2 2018 & WILL INCLUDE SOLIRIS SWITCH PATIENTS.  Full Article

Akari Therapeutics says priced public offering of american depositary shares
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Akari Therapeutics Plc :Akari therapeutics announces pricing of public offering of american depositary shares.Akari therapeutics plc - priced public offering of 3.5 million american depositary shares, or adss, at $5.00 per ads​.  Full Article

Akari Therapeutics treatment of guillain barré gets orphan drug status
Thursday, 12 May 2016 

Akari Therapeutics Plc :Akari Therapeutics announces receipt of orphan drug designation for Coversin from the U.S. FDA for treatment of guillain barré syndrome.  Full Article

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT